CPhI Announces USA Market Report at InformEx
Complete the form below to unlock access to ALL audio articles.
CPhI Worldwide, organized by UBM Live, has announced the launch of the CPhI Pharma Insights USA market report. A joint venture with InformEx, the report will provide European perspectives on the accessibility, growth and export market in the USA and is designed to encourage and increase trade harmonization between the two major pharma economies of the world.
The USA country report, which will be distributed in July 2014 follows the launch of the CPhI annual report (released at CPhI Worldwide, Frankfurt, October 2013).
The new report, which analyses current and future trends across the US pharma landscape will feature expert opinion from Europe’s leading companies, contrasted with US internal perceptions to provide a holistic view of the major trade flows within the region.
It will examine the areas in which European companies are looking to work with US counterparts, import into the US and, in particular, domestic and export manufacturing across pharma’s fine, specialty and custom chemicals market.
Following last year’s open access report covering the entire global industry, CPhI will now examine trends within specific leading pharma economies.
The global pharma industry meets each year at CPhI Worldwide to establish contacts, build relationships and cement partnerships, at CPhI events in high growth markets and at InformEx.
Now in its 25th year, CPhI is uniquely placed to collectively and independently assess industry perceptions, growth strategies and pharma market trends.
Chris Kilbee, Group Director, CPhI commented, “USA, as the largest pharma market, is a key driver of leading innovations across the global industry. CPhI is committed to analyzing the prominent pharma economies to help suppliers identify growth opportunities and encourage partnerships. European perspectives on the US market will generate insights that will be valuable, not only in Europe and the US, but also for any other regions looking to invest in, or work with, the World’s premier pharma economy”.
